Revenue Performance - Revenue for Q2 2025 was $1,005.3 million, a decrease of 1.2% compared to the prior year, but slightly above the guidance range of $995 to $1,005 million[2]. - Total revenues for the three months ended March 29, 2025, were $1,005.3 million, a slight decrease from $1,017.8 million for the same period in 2024, representing a decline of approximately 1.5%[22]. - Consolidated GAAP revenue for the three months ended March 29, 2025, was $1,005.3 million, a slight decrease of 1.5% compared to $1,017.8 million in the prior year[29]. - Organic revenue excluding COVID-19 for the six months ended March 29, 2025, was $1,902.5 million, a decrease of 0.4% from $1,909.3 million in the same period of 2024[29]. Earnings and Profitability - GAAP diluted EPS was a loss of ($0.08), down from $0.72 in the prior year, while non-GAAP diluted EPS was $1.03, flat compared to the prior year and at the high end of guidance[2][4]. - Net income for the three months ended March 29, 2025, was a loss of $17.4 million, compared to a net income of $169.9 million for the same period in 2024, indicating a significant decrease[22]. - GAAP net income for the three months ended March 29, 2025, was a loss of $17.4 million, while the previous year showed a profit of $169.9 million[31]. - Non-GAAP net income for the six months ended March 29, 2025, was $471.5 million, compared to $480.5 million in the same period last year[31]. - Adjusted EBITDA for the six months ended March 29, 2025, was $651.9 million, compared to $650.6 million in the prior year[31]. Revenue Segmentation - Diagnostics revenue increased by 0.8% to $453.6 million, primarily driven by higher molecular diagnostics sales, while organic diagnostics sales excluding COVID-19 grew by 4.5%[2][5]. - Breast Health revenue decreased by 7.4% to $356.2 million, primarily due to lower sales of mammography capital equipment[2][5]. - Surgical revenue grew by 4.2% to $162.5 million, driven by the addition of the acquired Gynesonics business and strong international sales[2][5]. Expenses and Costs - Operating expenses for the three months ended March 29, 2025, totaled $384.3 million, an increase from $331.9 million in the same period in 2024, marking an increase of approximately 15.7%[22]. - Research and development expenses for the three months ended March 29, 2025, were $61.5 million, down from $74.6 million in the same period in 2024, representing a decrease of about 17.5%[22]. - GAAP gross margin decreased by 1,580 basis points to 37.5%, primarily due to impairment charges on intangible assets[10]. Cash Flow and Financial Position - Cash flow from operations was $169.5 million, with cash and cash equivalents at $1.43 billion at the end of the quarter[10]. - Cash and cash equivalents at the end of the period were $1,429.5 million, down from $2,180.0 million, representing a decrease of 34.4%[26]. - Total assets decreased to $8,545.1 million from $9,156.0 million, a decline of approximately 6.7%[24]. - Total current liabilities decreased to $989.7 million from $1,037.2 million, a reduction of approximately 4.6%[24]. Shareholder Actions - The company repurchased 3.0 million shares for $200 million during the quarter[2]. - Repurchases of common stock amounted to $717.3 million during the six months ended March 29, 2025, compared to $676.8 million in the prior year[26]. Guidance and Future Expectations - Full-year revenue guidance for fiscal 2025 is maintained at $4,050 - $4,100 million, while non-GAAP EPS guidance is slightly lowered to $4.15 - $4.25[7][9]. - The company expects GAAP net income per share for the quarter ending June 28, 2025, to be between $0.85 and $0.88[33]. Impairment and Charges - The impairment of intangible assets for the three months ended March 29, 2025, was $183.4 million, significantly higher than $25.9 million for the same period in 2024[22]. - The company reported an impairment charge of $220.9 million for intangible assets during the six months ended March 29, 2025[26]. Return on Investment - Adjusted Return on Invested Capital (ROIC) was 13.7%, an increase of 30 basis points compared to the prior year[10]. - Adjusted return on invested capital (ROIC) for the trailing twelve months ended March 29, 2025, was 13.7%[35]. Geographic Revenue Breakdown - Geographic revenue breakdown for the three months ended March 29, 2025: United States 74.1%, Europe 14.6%, Asia-Pacific 5.9%, and Rest of World 5.4%[38].

Wall Street analysts forecast that Hologic (HOLX) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $1 billion, exhibiting a decline of 1.6% compared to the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections duri ...

Hologic, Inc.’s (HOLX)   fiscal 2025 second-quarter financial results, set to release on May 1 after the market closes, will likely see a solid performance of its GYN Surgical segment driven by its International strength. Molecular Diagnostics performance is expected to have strongly contributed to the Diagnostics division’s growth. In Breast Health, steady service revenues are expected to have helped offset the capital equipment softness.Meanwhile, check out our analysis to determine if the stock is worth ...

Core Viewpoint - Hologic (HOLX) is expected to report a decline in second-quarter fiscal 2025 earnings and revenues, with earnings estimated at $1.02 per share, reflecting a 0.97% year-over-year decrease, and revenues projected at $1.00 billion, indicating a 1.56% decline year over year [1][2] Earnings Performance - In the last four quarters, Hologic surpassed consensus estimates three times, with an average surprise of 2.53% [2] - The reported earnings history shows a slight variation from estimates, with the most recent quarter ending in December 2024 reporting $1.03 against an estimate of $1.02, resulting in a surprise of 0.98% [3] Earnings Expectations - Hologic has an Earnings ESP of 0.00%, indicating no expected surprise in the upcoming earnings report [4] - The company currently holds a Zacks Rank of 3 (Hold) [4] Challenges Impacting Performance - The company faces challenges such as macroeconomic volatility, supply-chain constraints, cost inflation, and a strengthening U.S. dollar, which are expected to negatively impact performance [5][6] - The Skeletal Health segment is projected to see a significant 32.8% year-over-year decline in sales due to shipment delays [6] Segment Performance - The Breast Health segment is anticipated to experience a 3.6% decline in revenues due to lower sales of capital equipment [7] - The Diagnostics division is expected to show modest growth of 0.5%, driven by strong sales in its core Molecular business [9] - The GYN Surgical segment is likely to see a 3% year-over-year revenue increase, supported by strong international sales [11] Stock Performance - Hologic shares have declined 4.2% over the past 30 days, performing better than the industry average decline of 9% and the S&P 500's 7% decline [12] - The stock is trading at a forward P/E of 13.05X, which is lower than the industry average of 27.41X, indicating a more attractive valuation [16] Investment Thesis - Hologic's molecular diagnostics business has significant growth potential, and the company holds a strong market position in Breast Health with plans for future product launches [19] - Recent acquisitions, such as Endomagnetics and Gynesonics, reflect the company's strong balance sheet and commitment to growth [20] - The company aims for double-digit earnings growth through a combination of steady revenue growth, margin expansion, and strategic acquisitions [20] International Growth Strategy - Hologic is focusing on international growth by going direct in more markets, with the International Surgical business showing over 20% growth [21] - The company expects its international revenues in cytology and STI testing to become significant revenue drivers over time [21] Long-term Outlook - Despite current macroeconomic pressures, Hologic's Diagnostics division is expected to perform well, and the company is well-positioned for long-term growth through its core business performance and acquisitions [22]

Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global Cellulite Treatment Market was valued at USD 1.57 billion in 2024 and is expected to reach USD 2.47 billion by 2030 with a CAGR of 7.84% during the forecast period. The global cellulite treatment market is a dynamic and rapidly growing segment within the broader healthcare and wellness i ...

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035. Two prominent companies with a strong foothold in this space are Hologic (HOLX) and Myriad Genetics (MYGN) . Hologic’s molecular diagnostics offerings specialize in women’s health and acute respirator ...

Core Insights - Hologic appointed Wayde McMillan to its board, enhancing its financial expertise and understanding of the MedTech industry [1][2] - The company's stock performance has been relatively resilient compared to industry peers, with a 7.2% decline over the past month, less than the industry's 10.3% drop [3] Company Developments - Hologic's board now includes a finance veteran, which is expected to positively impact the company's strategic direction [1][2] - The stock saw a 2.6% increase in after-hours trading following the announcement of McMillan's appointment [2] Financial Performance - Hologic's stock has outperformed Medtronic and Abbott, which experienced declines of 11.6% and 9.4%, respectively [3] - The company anticipates a revenue impact of up to $30 million for fiscal 2025 due to external disruptions, including the freezing of U.S. foreign assistance funds [9] Market Challenges - Hologic faces challenges from new tariffs imposed on products manufactured in Costa Rica and Mexico, which could increase operational costs [8] - The company has cut its fiscal 2025 revenue projections by $100 million, now targeting a range of $4.15-$4.20 billion [10] Growth Opportunities - Hologic's Diagnostics division remains a key strength, with growth driven by its Molecular Diagnostics and Biotheranostics lab testing business [14] - The company is focusing on international expansion, particularly in underpenetrated markets, which presents significant growth potential [16][18] Valuation Metrics - Hologic's forward P/E ratio is 13.66X, significantly lower than the industry average of 26.54X, indicating a favorable valuation position [19][21]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月8日至11日， 第91届中国国际医疗器械（春季）博览会（CMEF） 将在上海国家会展中心拉开帷幕。作为亚太地区规模最大的医疗科技展会，CMEF始终 是行业风向标，不仅汇聚全球创新技术，更见证着产业发展的新趋势。本届展会预计吸引 全球30多个国家和地区的近 5000家 企业，携 数万款 前沿产品集中亮相 ，以"创新科技，智领未来"为主题，共同探讨医疗科技的突破与未来。 CMEF不仅是一场产品与技术的集中展示，更是医疗行业生态的一次深度联动。从人工智能驱动的医学影像，到手术机器人赋能精准医疗，从智慧医院建设，到国 产医疗设备的崛起，CMEF2025通过高规格论坛、产业对话和技术展示，构建起全方位的交流平台，为行业发展提供新的思路与动能。 在这一医疗科技的年度盛会上，哪些企业将携最新技术亮相？哪些创新产品值得重点关注？ 思宇梳理了本届CMEF的亮点企业，一起来看它们如何在这场科技盛宴 中抢占先机！ P.S. 展位图附于文末，感兴趣的读者可按图索骥 ...

Core Insights - Hologic (HOLX) is experiencing growth driven by new product launches in Diagnostics and Breast Health, but macroeconomic challenges and unfavorable foreign exchange (FX) conditions are hindering its overall performance [1][8]. Product Developments - The introduction of the Envision Mammography Platform, the first FDA-approved technology of its kind, is expected to enhance Hologic's offerings with a leading 2.5-second scan time, set for commercial launch next year [2]. - Hologic is launching the next-generation Genius AI Detection PRO solution in the U.S., which builds on the previous version to improve accuracy and efficiency in cancer screening, addressing racial bias concerns in AI-driven diagnoses [3]. Business Performance - The Surgical business is showing strong performance, with over 20% growth in the International Surgical segment in the first quarter of fiscal 2025, indicating optimism for future expansion [4]. - The molecular diagnostics segment is a key revenue driver, contributing 11% to revenues in the first quarter of fiscal 2025, excluding COVID-19 sales, with strong growth in the BV CV/TV assay and core women's health assays [5]. Strategic Initiatives - Hologic is implementing strategies to streamline operations and reduce costs, including targeted investments in marketing campaigns and initiatives to gain market share [6]. Market Challenges - The stock has declined 18.6% over the past year, compared to a 7.7% decline in the industry, but there are expectations for recovery as the company focuses on expanding its diagnostic and breast health offerings [7]. - Concerns about a potential recession and global supply constraints are impacting the company's ability to meet demand and increasing costs [8]. - Hologic has reduced its full-year revenue guidance by $100 million to a range of $4.05 billion to $4.10 billion due to a reassessment of market trends and a stronger U.S. dollar, which is expected to create a $20 million FX headwind for fiscal 2025 [9][12].

Core Viewpoint - Hologic (HOLX) has faced significant stock decline of 24.7% over the past six months, underperforming compared to the industry and S&P 500 [1] - The company is navigating challenges from geopolitical shifts, economic pressures, and internal divisional weaknesses, leading to a cautious fiscal outlook for 2025 [22] Financial Performance - Hologic's stock reached a 52-week low of $60.34, influenced by broader economic pressures and a subdued earnings report [4] - Revenue growth was limited to 0.9% year-over-year, with a $30 million foreign exchange headwind projected for the full year [8] - The company revised its revenue guidance for fiscal 2025 down to $4.05 billion to $4.10 billion, a reduction of $100 million from previous estimates [8] Market Challenges - The company faces uncertainties due to U.S. policy shifts, particularly affecting its partnership with PEPFAR for HIV testing, potentially impacting revenues by up to $30 million [5] - Recent tariffs may challenge profitability for products imported from Mexico, alongside increased production and storage costs due to supply-chain constraints [6] - The Breast Health unit is expected to have a softer year, with a 2.1% decline in sales and a 37.4% drop in Skeletal revenues due to shipment delays [7] Strategic Initiatives - Hologic emphasizes strategic acquisitions to drive growth, including Biotheranostics and Gynesonics, which are expected to enhance margins and expand product offerings [12][13] - The company is focusing on international expansion, particularly in underpenetrated markets, leveraging its strong product portfolio [14][15] Innovations and Opportunities - Hologic is introducing advanced AI-powered breast imaging technologies, such as the Envision platform and Genius AI Detection PRO, which are generating significant market interest [16][17] - The company is well-positioned to capture emerging market opportunities with its innovative offerings and strong brand presence [15] Valuation - Hologic shares are trading at a forward price-to-earnings (P/E) ratio of 13.96X, significantly lower than the industry average of 29.22, indicating a potentially undervalued stock [19]